Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02215


The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.

Study summary:

Subjects with non-cirrhotic hepatitis C will have a magnetic resonance imaging (MRI)/magnetic resonance (MR) spectroscopy and neuropsychological testing prior to starting interferon. Subjects will have repeat testing following 12 weeks of interferon therapy and again at 12 weeks post interferon therapy. MR spectroscopy (MRS) will measure the cerebral metabolites, NAA (N-acetyl aspartate), Cho (choline), MI (myoinositol) and Cr (creatine) at 3 distinct brain regions, i.e. basal ganglia and 2 locations within the frontal cortex. Neuropsychological testing will include tests of the following cognitive domains: executive functioning, memory, language, motor skills and will also include questionnaires pertaining to quality of life (SF-36), mood (Beck's depression inventory) and a self-rating cognitive questionnaire (Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scales [CAARS]). Control subjects will include non-cirrhotic HCV subjects who are not taking interferon therapy.


Inclusion Criteria: - Adults (>18 years old) of both sexes with chronic HCV infection (all genotypes). - Subjects due to start treatment with pegylated interferon-alpha (IFN-a) for HCV eradication. - Subjects with chronic hepatitis C who have elected not to be treated with pegylated-IFN-a - Subjects with mild fibrosis on liver biopsy (stage 0-III/IV fibrosis) - Subjects able to give informed consent. - Subjects with controlled depression currently taking anti-depressant medication. Exclusion Criteria: - Subjects with cirrhosis on liver biopsy. - Subjects with active alcohol or drug abuse. - Subjects co-infected with human immunodeficiency virus (HIV). - Subjects with structural brain abnormality, past history of cerebrovascular accident (CVA) or serious head trauma. - Subjects with seizure disorder. - Subjects with any contraindication to IFN therapy. - Subjects with a poor command of the English language. - Subjects with a contraindication to MRI, e.g. pacemaker, claustrophobia.



Primary Contact:

Principal Investigator
Nezam Afdhal, MD
Beth Israel Deaconess Medical Center

Valerie Byrnes, MD
Phone: 617 632 1070
Email: vbyrnes@bidmc.harvard.edu

Backup Contact:


Location Contact:

Boston, Massachusetts 02215
United States

Valerie Byrnes, MD
Phone: 617-632-1070
Email: vbyrnes@bidmc.harvard.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.